BRAF and cutaneous melanoma: Nevertheless, it may not represent the optimal approach for all patients and should be carefully evaluated on an individual basis, considering specific tumor characteristics such as mutational status to guide treatment selection.<h4>Case presentation</h4>We report the clinical case of a patient with cutaneous melanoma initially diagnosed as stage IIIA, harboring BRAF V600E mutation, who did not receive any adjuvant therapy and developed locoregional recurrence within one year from diagnosis.